Analysts expect that Illumina, Inc. (NASDAQ:ILMN) will announce sales of $825.07 million for the current quarter, Zacks Investment Research reports. Six analysts have provided estimates for Illumina’s earnings. The highest sales estimate is $838.99 million and the lowest is $775.00 million. Illumina posted sales of $714.00 million in the same quarter last year, which would indicate a positive year over year growth rate of 15.6%. The business is expected to announce its next quarterly earnings report after the market closes on Tuesday, October 23rd.
On average, analysts expect that Illumina will report full year sales of $3.31 billion for the current financial year, with estimates ranging from $3.23 billion to $3.38 billion. For the next financial year, analysts anticipate that the firm will post sales of $3.77 billion, with estimates ranging from $3.54 billion to $4.06 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that follow Illumina.
Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Monday, July 30th. The life sciences company reported $1.43 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.11 by $0.32. The business had revenue of $830.00 million during the quarter, compared to analyst estimates of $786.88 million. Illumina had a net margin of 20.88% and a return on equity of 26.64%. The business’s revenue was up 25.4% on a year-over-year basis. During the same period last year, the business earned $0.82 EPS.
In other news, Director Jay T. Flatley sold 3,300 shares of the firm’s stock in a transaction dated Wednesday, October 10th. The shares were sold at an average price of $321.58, for a total value of $1,061,214.00. Following the transaction, the director now directly owns 385,604 shares in the company, valued at approximately $124,002,534.32. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Robert S. Epstein sold 500 shares of the firm’s stock in a transaction dated Monday, July 23rd. The stock was sold at an average price of $311.15, for a total transaction of $155,575.00. Following the completion of the transaction, the director now owns 6,139 shares in the company, valued at $1,910,149.85. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 52,483 shares of company stock worth $17,702,063. Insiders own 0.54% of the company’s stock.
Several institutional investors have recently bought and sold shares of the company. Argus Investors Counsel Inc. lifted its position in shares of Illumina by 17.1% in the 3rd quarter. Argus Investors Counsel Inc. now owns 1,445 shares of the life sciences company’s stock worth $530,000 after buying an additional 211 shares during the last quarter. Nisa Investment Advisors LLC lifted its position in shares of Illumina by 113.7% in the 3rd quarter. Nisa Investment Advisors LLC now owns 53,715 shares of the life sciences company’s stock worth $19,717,000 after buying an additional 28,580 shares during the last quarter. Raymond James Trust N.A. bought a new position in shares of Illumina in the 3rd quarter worth about $226,000. Andra AP fonden lifted its position in shares of Illumina by 23.4% in the 3rd quarter. Andra AP fonden now owns 15,300 shares of the life sciences company’s stock worth $5,616,000 after buying an additional 2,900 shares during the last quarter. Finally, First Hawaiian Bank bought a new position in shares of Illumina in the 3rd quarter worth about $384,000. Institutional investors own 89.84% of the company’s stock.
Shares of ILMN stock opened at $326.58 on Wednesday. The firm has a market cap of $53.96 billion, a price-to-earnings ratio of 79.50, a P/E/G ratio of 3.04 and a beta of 0.97. The company has a quick ratio of 2.44, a current ratio of 2.74 and a debt-to-equity ratio of 0.22. Illumina has a 1-year low of $198.21 and a 1-year high of $372.61.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
Further Reading: Risk Tolerance
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.